- Report
- April 2025
- 208 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- May 2024
- 133 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 133 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- April 2023
- 115 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- March 2024
- 168 Pages
Global
€4546EUR$4,995USD£3,897GBP
- Report
- February 2024
- 102 Pages
Global
From €3500EUR$4,120USD£3,106GBP
Sofosbuvir is a prescription drug used to treat chronic hepatitis C virus (HCV) infection. It is a nucleotide analog inhibitor of the HCV NS5B polymerase, which is an enzyme that is essential for viral replication. Sofosbuvir is usually used in combination with other antiviral medications, such as ribavirin or peginterferon alfa, to treat HCV infection. It is also used to treat liver and kidney disorders, such as cirrhosis, chronic kidney disease, and end-stage renal disease.
Sofosbuvir is a relatively new drug, having been approved by the U.S. Food and Drug Administration (FDA) in 2013. It is available in both generic and brand-name formulations. The brand-name formulation is marketed under the trade name Sovaldi.
The market for sofosbuvir is highly competitive, with several major pharmaceutical companies offering the drug. These include Gilead Sciences, Mylan, Teva Pharmaceuticals, and Cipla. Show Less Read more